中文摘要：

目的将在保护肾，支持的接枝工作并且改进 transplanted 以后肾恢复上调查 diltiazem 和 cyclosporine A (CsA ) 联合治疗的效果。方法 CsA， transplant 以后肾的条件，尖锐拒绝(AR ) 的率，以及在 636 种情况中的肝、肾的毒性的血集中肾移植接受者在被 CsA 对待以后被决定，与或没有 diltiazem。与收到了 CsA ， mycophenolate mofetil ( MMF )和氢化尼松( Pred )，但是缺乏 diltiazem 的控制组相比结果，和要求的 diltiazem 收到这些代理人的组减少了 CsA 的剂量( P < 0.01 )，当 CsA 的血集中显著地被增加时( P < 0.01 )；接枝功能的恢复时间被减少从(6.2 卤 1 .5 ) d 到(3.9 卤 1 .4 ) d (P < 0.01 ) ，并且 AR 的率从 13.2% ～ 7.9% 被减少(P < 0.01 ) 。在与 CsA 和 diltiazem 对待的肾的移植病人的结论，当剂量被减少时， CsA 的血集中被增加。这有效联合治疗减少了病人的经济负担，同时保留了肾功能，支持了接枝功能恢复并且减少肝、肾的毒性和 AR 的率。

英文摘要：

Objective： To investigate the effects of diltiazem and cyclosporine A （CsA） combination therapy on protecting the kidney, promoting graft functioning and improving post-transplanted kidney recovery. Methods： The blood con- centrations of CsA, the condition of the post-transplant kidney, the rate of acute rejection （AR）, as well as hepatic and renal toxicity in 636 cases of renal transplant recipients were determined after being treated by CsA, with or without diltiazem. Results： Compared with the control group which received CsA, mycophenolate mofetil （MMF） and prednisolone （Pred） but lacked diltiazem, the group receiving these agents together with diltiazem required reduced dosage of CsA （P 〈 0.01）, while blood concentrations of CsA were significantly increased （P 〈 0.01）; the recovery time of graft function was reduced from （6.2± 1.5） d to （3.9± 1.4） d （P 〈 0.01）, and the rate of AR was decreased from 13.2% to 7.9% （P 〈 0.01）. Conclusion： In renal transplantation patients treated with CsA and diltiazem, blood concentrations of CsA were increased while the dosage was decreased. This efficient combination therapy reduced patients economic burden, at the same time retained kidney function, promoted graft function recovery and decreased hepatic and renal toxicity and the rate of AR.